Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naive Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study